NZ: GSK hit by further Ribena vitamin C damage

By | 27 March 2007

GlaxoSmithKline has followed last week's Australia vitamin C scandal with fines in New Zealand.

The company has been fined NZ$227,500 (US$316,000) in New Zealand for breaching fair trading laws regarding the vitamin C content of its pre-mixed Ribena. Last week , GSK "self-reported" discrepancies in its claims about vitamin C content in Ribena on sale in Australia.

GlaxoSmithKline admitted to the court in New Zealand that its Ribena did not contain any vitamin C, despite claims that it contained seven milligrams of the vitamin per 100 millilitres. The issue came to light when two New Zealand schoolgirls conducted experiments on the drink and discovered the lack of vitamin C. The two girls told local press that their claims to the company were initially ignored.

"The fact that some of our products had incorrect labelling is to us, unacceptable, and we sincerely regret any confusion caused to customers who feel they may have been misled," the company said today in a statement.

No-one was available for further comment at GlaxoSmithKline when contacted by just-drinks today (27 March).

Sectors: Soft drinks, Water

View next/previous articles

Currently reading -

NZ: GSK hit by further Ribena vitamin C damage

There are currently no comments on this article

Be the first to comment on this article

Read more on this hot issue

Just the Answer - GlaxoSmithKline

In the wake of a scandal in Australia and New Zealand where GlaxoSmithKline (GSK) was fined for misrepresenting the Vitamin C level of its Ribena brand, Graham Neale, general manager at Nutritional Healthcare UK, the GSK subsidiary that produces Lucozade, Ribena and Horlicks, takes the opportunity of this month’s Just the Answer interview to put his company’s side of the story and outline future plans for both Ribena and Lucozade.

just-drinks tagline

Not a member? Join here

Decrease font sizeDecrease font sizeDecrease font size Increase font sizeIncrease font sizeIncrease font size Comment on this article Email this to a friend Print this page